We narrowed to 1,364 results for: EYFP

#20949-AAV9

Ready-to-use AAV9 particles produced from pAAV-double floxed-eNpHR-EYFP-WPRE-pA (#20949). In addition to the viral particles, you will also receive purified pAAV-double floxed-eNpHR-EYFP-WPRE-pA plasmid DNA. EF1a-driven, cre-dependent eNpHR EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

July 12, 2018

Academic Institutions and Nonprofits only

#26968-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 21, 2018

Academic Institutions and Nonprofits only

#117382-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#117382-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Oct. 18, 2021

Academic Institutions and Nonprofits only

#35505-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-hChR2(E123A)-EYFP (#35505). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(E123A)-EYFP plasmid DNA. CaMKIIa-driven hChR2(E123A)-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

May 24, 2018

Academic Institutions and Nonprofits only

#26973-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-hChR2(H134R)-EYFP (#26973). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-EYFP plasmid DNA. hSyn-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 27, 2024

Academic Institutions and Nonprofits only

#137163-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-EYFP (#137163). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-EYFP for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#137155-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-iC++-EYFP (#137155). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-iC++-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Dec. 1, 2020

Academic Institutions and Nonprofits only